Can you do it? Can you ace these quiz questions about EGPA? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your physician colleagues ...

Granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis) Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) IgA vasculitis (previously known as Henoch ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

eosinophilic granulomatosis with polyangiitis in adults and hypereosinophilic syndrome in patients aged 12+. Currently, the drug is not approved for COPD worldwide. In the past three months ...

For those of us diagnosed with a rare disease, the Orphan Drug Act of 1982 has been a lighthouse of hope for a perilous journey. The ODA recognized the lethal ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

It may also be used to treat eosinophilic granulomatosis with polyangiitis (EGPA) in adults. Keep reading to learn about the common, mild, and serious side effects Fasenra can cause. To learn more ...